認知症治療の市場規模、シェア、動向分析レポート：適応症別、薬剤クラス別、投与経路別、流通チャネル別、地域別、セグメント予測、2025年～2030年

認知症治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の認知症治療市場規模は2025～2030年にかけてCAGR 8.0％を記録し、2030年までに281億1,000万米ドルに達すると予測されています。

認知症患者の増加、新薬の導入、効果的な治療法を開発するための市場関係者や研究機関の関与の増加は、市場成長を促進する主要要因の一部です。2023年9月に発表されたCross River Therapyのデータによると、英国におけるアルツハイマー病（AD）の有病率は人口10万人当たり約42.70人で、人口1人当たりの患者数が2番目に多い国となっています。

認知症治療のための啓発キャンペーンや新規治療法を開発するための研究活動を支援するために、政府や非政府機関によって実施される有利なイニシアチブの増加は、市場の成長を促進すると予想されます。例えば、2022年2月、マギル大学の認知症教育プログラムは、カナダ公衆衛生局から資金提供を受け、病気に関する認知度を高めるための15のプロジェクトを開始しました。認知症コミュニティ投資（DCI）は75万8,430米ドルを投じて、同大学の「Ten Online Modules over Ten Weeks for Adult Learners」（TOTAL）eラーニングを支援し、介護者の間に認知を広める予定です。

学術研究機関はさらに、さまざまなタイプの認知症の研究や、全体的な疾病負担を軽減するための効果的な治療の開発などの研究活動に取り組んでいます。例えば、2024年2月、コロラド大学アンシュッツメディカルキャンパスの研究者は、Mdm2タンパク質と治験中の抗がん剤ヌートリンが、アルツハイマー病に関連するシナプスと樹状突起スパインの破壊を防ぐことができることを発見しました。さらに2023年12月、ペンシルバニア大学ペレルマン医療部の前臨床研究で、シャペロン分子が脳の老化や記憶障害を含む病気の兆候を逆転させることができる特定のタンパク質を配合することが示されました。

市場開拓者は、認知症に対する効果的で安全な治療法を開発する能力を高めるために、地域参入企業や研究機関と協力しています。2021年2月、ExscientiaとOxford大学はアルツハイマー病の治療法開発で提携しました。さらに、Eisai Co., Ltd.とBiogenは、認知症の効果的な治療法を早期に開発するために提携しました。これらの企業はアデュカヌマブとレカネマブを共同開発しました。両社は世界中の主要な規制当局からこれらの薬剤の市場承認を受けています。

認知症治療市場レポートハイライト

• AD認知症は有病率が高く、承認薬も多いことから、2024年には59.8%のシェアを占め、適応症セグメント市場を独占しました。
• レビー小体型認知症（LBD）セグメントは、発症率と重症度の増加により、2025～2030年にかけて最も速いCAGRで成長すると予測されます。
• コリンエステラーゼ阻害剤セグメントは、経口と経皮パッチの配合率が高いことから、2024年に最大のシェアを占めました。
• 配合剤セグメントは、配合剤の有効性と採用率の増加により、2025～2030年にかけてCAGRが最も速くなると予測されています。
• 注射剤セグメントは、生物製剤の導入と有望な注射剤のパイプラインの存在により、2025～2030年にかけて最も速いCAGRを記録すると予測されます。
• 2024年の世界市場は北米が支配的であったが、これは同地域の疾患有病率の高さ、強力な市場参入企業の存在、より良い償還施策などの要因によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 認知症治療市場の変数、動向、範囲

• 市場系統の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 産業分析-ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析

第4章 認知症治療市場：適応症ビジネス分析

• 適応症市場シェア、2024年と2030年
• 適応症セグメントダッシュボード
• 市場規模と予測と動向分析、適応症別、2018～2030年
• アルツハイマー病認知症
• 血管性認知症
• レビー小体型認知症
• 前頭側頭型認知症（FTD）
• パーキンソン病認知症
• その他

第5章 認知症治療市場：薬剤クラスビジネス分析

• 薬剤クラス市場シェア、2024年と2030年
• 薬剤クラスセグメントダッシュボード
• 市場規模と予測と動向分析、薬剤クラス別、2018～2030年
• コリンエステラーゼ阻害剤
• NMDA受容体拮抗薬
• MAO阻害剤
• 併用薬
• その他

第6章 認知症治療市場：投与経路ビジネス分析

• 投与経路市場シェア、2024年と2030年
• 投与経路セグメントダッシュボード
• 市場規模と予測と動向分析、投与経路別、2018～2030年
• 経口
• 経皮パッチ
• 注射

第7章 認知症治療市場：流通チャネルビジネス分析

• 流通チャネル市場シェア、2024年と2030年
• 流通チャネルセグメントダッシュボード
• 市場規模と予測と動向分析、流通チャネル別、2018～2030年
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 認知症治療市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 国別、2018～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 国別、2018～2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • デンマーク
  • スウェーデン
• アジア太平洋
  • 国別、2018～2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • 国別、2018～2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 国別、2018～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Novartis AG
  • DAIICHI SANKYO COMPANY, LIMITED
  • AbbVie Inc.
  • Lundbeck
  • Biogen
  • Cipla
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Global dementia treatment market, by region, 2018 - 2030 (USD Million)
• Table 4. Global dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 5. Global dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 6. Global dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 7. Global dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 8. North America dementia treatment market, by country, 2018 - 2030 (USD Million)
• Table 9. North America dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 10. North America dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 11. North America dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 12. North America dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 13. U.S. dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 14. U.S. dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 15. U.S. dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 16. U.S. Dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 17. Canada dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 18. Canada dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 19. Canada dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 20. Canada dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 21. Mexico dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 22. Mexico dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 23. Mexico dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 24. Mexico dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 25. Europe dementia treatment market, by country, 2018 - 2030 (USD Million)
• Table 26. Europe dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 27. Europe dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 28. Europe dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 29. Europe dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 30. UK dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 31. UK dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 32. UK dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 33. UK Dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 34. Germany dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 35. Germany dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 36. Germany dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 37. Germany dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 38. France dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 39. France dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 40. France dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 41. France Dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 42. Italy dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 43. Italy dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 44. Italy dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 45. Italy dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 46. Spain dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 47. Spain dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 48. Spain dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 49. Spain dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 50. Norway dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 51. Norway dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 52. Norway dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 53. Norway Dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 54. Denmark dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 55. Denmark dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 56. Denmark dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 57. Denmark dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 58. Sweden dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 59. Sweden dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 60. Sweden dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 61. Sweden dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 62. Asia Pacific dementia treatment market, by country, 2018 - 2030 (USD Million)
• Table 63. Asia Pacific dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 64. Asia Pacific dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 65. Asia Pacific dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 66. Asia Pacific dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 67. Japan dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 68. Japan dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 69. Japan dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 70. Japan dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 71. China dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 72. China dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 73. China dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 74. China dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 75. India dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 76. India dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 77. India dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 78. India dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 79. Australia dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 80. Australia dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 81. Australia dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 82. Australia dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 83. South Korea dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 84. South Korea dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 85. South Korea dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 86. South Korea dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 87. Thailand dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 88. Thailand dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 89. Thailand dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 90. Thailand dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 91. Latin America dementia treatment market, by country, 2018 - 2030 (USD Million)
• Table 92. Latin America dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 93. Latin America dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 94. Latin America dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 95. Latin America dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 96. Brazil dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 97. Brazil dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 98. Brazil dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 99. Brazil dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 100. Argentina dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 101. Argentina dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 102. Argentina dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 103. Argentina dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 104. Middle East & Africa Dementia treatment market, by country, 2018 - 2030 (USD Million)
• Table 105. Middle East & Africa dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 106. Middle East & Africa dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 107. Middle East & Africa dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 108. Middle East & Africa dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 109. South Africa dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 110. South Africa dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 111. South Africa dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 112. South Africa dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 113. Saudi Arabia dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 114. Saudi Arabia dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 115. Saudi Arabia dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 116. Saudi Arabia dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 117. UAE dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 118. UAE dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 119. UAE dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 120. UAE dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 121. Kuwait dementia treatment market, by indication, 2018 - 2030 (USD Million)
• Table 122. Kuwait dementia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 123. Kuwait dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 124. Kuwait dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Dementia treatment market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Indication and drug class outlook (USD Million)
• Fig. 10 Route of administration and distribution channel outlook (USD Million)
• Fig. 11 Competitive landscape
• Fig. 12 Dementia treatment market dynamics
• Fig. 13 Dementia treatment market: Porter's five forces analysis
• Fig. 14 Dementia treatment market: PESTLE analysis
• Fig. 15 Dementia treatment market: Indication segment dashboard
• Fig. 16 Dementia treatment market: Indication market share analysis, 2024 & 2030
• Fig. 17 Alzheimer's disease dementia market, 2018 - 2030 (USD Million)
• Fig. 18 Vascular dementia market, 2018 - 2030 (USD Million)
• Fig. 19 Lewy body dementia market, 2018 - 2030 (USD Million)
• Fig. 20 Frontotemporal dementia (FTD) market, 2018 - 2030 (USD Million)
• Fig. 21 Parkinson disease dementia market, 2018 - 2030 (USD Million)
• Fig. 22 Others market, 2018 - 2030 (USD Million)
• Fig. 23 Dementia treatment market: Drug class segment dashboard
• Fig. 24 Dementia treatment market: Drug class market share analysis, 2024 & 2030
• Fig. 25 Cholinesterase inhibitors market, 2018 - 2030 (USD Million)
• Fig. 26 NMDA receptor antagonist market, 2018 - 2030 (USD Million)
• Fig. 27 MAO inhibitors market, 2018 - 2030 (USD Million)
• Fig. 28 Combination drugs market, 2018 - 2030 (USD Million)
• Fig. 29 Others market, 2018 - 2030 (USD Million)
• Fig. 30 Dementia treatment market: Route of administration segment dashboard
• Fig. 31 Dementia treatment market: Route of administration market share analysis, 2024 & 2030
• Fig. 32 Oral market, 2018 - 2030 (USD Million)
• Fig. 33 Transdermal patch market, 2018 - 2030 (USD Million)
• Fig. 34 Injectable market, 2018 - 2030 (USD Million)
• Fig. 35 Dementia treatment market: Distribution channel segment dashboard
• Fig. 36 Dementia treatment market: Distribution channel market share analysis, 2024 & 2030
• Fig. 37 Hospital pharmacies market, 2018 - 2030 (USD Million)
• Fig. 38 Retail pharmacies market, 2018 - 2030 (USD Million)
• Fig. 39 Online pharmacies market, 2018 - 2030 (USD Million)
• Fig. 40 Dementia treatment market revenue, by region
• Fig. 41 Regional marketplace: Key takeaways
• Fig. 42 Regional marketplace: Key takeaways
• Fig. 43 North America dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 44 U.S. country dynamics
• Fig. 45 U.S. dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 46 Canada country dynamics
• Fig. 47 Canada dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 48 Mexico country dynamics
• Fig. 49 Mexico dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 50 Europe dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 51 UK country dynamics
• Fig. 52 UK dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 53 Germany country dynamics
• Fig. 54 Germany dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 55 France country dynamics
• Fig. 56 France dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 57 Italy country dynamics
• Fig. 58 Italy dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 59 Spain country dynamics
• Fig. 60 Spain dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 61 Norway country dynamics
• Fig. 62 Norway dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 63 Sweden country dynamics
• Fig. 64 Sweden dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 65 Denmark country dynamics
• Fig. 66 Denmark dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 67 Asia Pacific dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 68 Japan country dynamics
• Fig. 69 Japan dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 70 China country dynamics
• Fig. 71 China dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 72 India country dynamics
• Fig. 73 India dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 74 Australia country dynamics
• Fig. 75 Australia dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 76 South Korea country dynamics
• Fig. 77 South Korea dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 78 Thailand country dynamics
• Fig. 79 Thailand dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 80 Latin America dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 81 Brazil country dynamics
• Fig. 82 Brazil dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 83 Argentina country dynamics
• Fig. 84 Argentina dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 85 MEA dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 86 South Africa country dynamics
• Fig. 87 South Africa dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 88 Saudi Arabia country dynamics
• Fig. 89 Saudi Arabia dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 90 UAE country dynamics
• Fig. 91 UAE dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 92 Kuwait country dynamics
• Fig. 93 Kuwait dementia treatment market, 2018 - 2030 (USD Million)
• Fig. 94 Company categorization
• Fig. 95 Company market position analysis
• Fig. 96 Strategic framework

Dementia Treatment Market Growth & Trends:

The global dementia treatment market size is anticipated to reach USD 28.11 billion by 2030, registering a CAGR of 8.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing patient base of dementia, introduction of novel drugs, and increasing involvement of market players and research institutes to develop effective treatment for the disease are some of key factors driving market growth. According to the Cross River Therapy data published in September 2023, the prevalence of Alzheimer's disease (AD) in the UK is around 42.70 cases per 100,000 people, which makes it the country with the second-greatest number of cases per capita.

Increasing favorable initiatives undertaken by government and non-government bodies to support the awareness campaign and research activities to develop novel therapies for dementia treatment are anticipated to fuel market growth. For instance, in February 2022, McGill University's Dementia Education Program initiated 15 projects funded by the Public Health Agency of Canada to increase awareness about the disease. The Dementia Community Investment (DCI) is going to invest USD 758,430 to support the University's Ten Online Modules over Ten Weeks for Adult Learners (TOTAL) eLearning to spread awareness among caregivers.

Academic and research institutes are further involved in research activities to study different types of dementia and development of effective therapeutics to reduce the overall disease burden. For instance, in February 2024, researchers at the University of Colorado Anschutz Medical Campus found that Mdm2 protein with an investigational cancer drug, nutlin, can prevent the destruction of synapses and dendritic spines associated with Alzheimer's disease. Moreover, in December 2023, A preclinical study from the Perelman School of Medicine at the University of Pennsylvania showed that a chaperone molecule formulated specific proteins that can reverse disease signs including aging brain and memory impairment.

Market players are collaborating with regional players and research institutions to increase their capabilities to develop effective and safe therapy for dementia. In February 2021, Exscientia and the University of Oxford tied up to develop therapies for Alzheimer's disease. Moreover, Eisai Co., Ltd. and Biogen partnered to develop effective therapies for dementia earlier. These companies have jointly developed aducanumab and lecanemab. The companies are receiving market approvals for these drugs from key regulatory authorities across the globe.

Dementia Treatment Market Report Highlights:

• The AD dementia segment dominated the indication segment market with a share of 59.8% in 2024 owing to a high prevalence of AD dementia and approved drugs
• The Lewy body dementia (LBD) segment is expected to grow at the fastest CAGR from 2025 to 2030 owing to the increasing incidence and severity of the disease
• The cholinesterase inhibitors segment held the largest share in 2024 owing to high prescription rate of oral and transdermal patches of these drugs
• The combination drug segment is projected to experience the fastest CAGR from 2025 to 2030 owing to increased effectiveness and adoption of combination drugs
• The injectables route of administration segment is anticipated to register the fastest CAGR from 2025 to 2030 owing to the introduction of biological drugs and the presence of promising injectable drugs in the pipeline
• North America dominated the global market in 2024 owing to factors, such as high disease prevalence, presence of strong market players, and better reimbursement policies in the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Drug Class
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Dementia Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis

Chapter 4. Dementia Treatment Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2030
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 4.4. Alzheimer's Disease Dementia
  • 4.4.1. Alzheimer's Disease Dementia Market, 2018 - 2030 (USD Million)
• 4.5. Vascular Dementia
  • 4.5.1. Vascular Dementia Market, 2018 - 2030 (USD Million)
• 4.6. Lewy Body Dementia
  • 4.6.1. Lewy Body Dementia Market, 2018 - 2030 (USD Million)
• 4.7. Frontotemporal Dementia (FTD)
  • 4.7.1. Frontotemporal Dementia (FTD) Market, 2018 - 2030 (USD Million)
• 4.8. Parkinson Disease Dementia
  • 4.8.1. Parkinson Disease Dementia Market, 2018 - 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Dementia Treatment Market: Drug Class Business Analysis

• 5.1. Drug Class Market Share, 2024 & 2030
• 5.2. Drug Class Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 5.4. Cholinesterase Inhibitors
  • 5.4.1. Cholinesterase Inhibitors Market, 2018 - 2030 (USD Million)
• 5.5. NMDA Receptor Antagonist
  • 5.5.1. NMDA Receptor Antagonist Market, 2018 - 2030 (USD Million)
• 5.6. MAO Inhibitors
  • 5.6.1. MAO Inhibitors Market, 2018 - 2030 (USD Million)
• 5.7. Combination Drugs
  • 5.7.1. Combination Drugs Market, 2018 - 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Dementia Treatment Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2024 & 2030
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Oral
  • 6.4.1. Oral Market, 2018 - 2030 (USD Million)
• 6.5. Transdermal Patch
  • 6.5.1. Transdermal Patch Market, 2018 - 2030 (USD Million)
• 6.6. Injectable
  • 6.6.1. Injectable Market, 2018 - 2030 (USD Million)

Chapter 7. Dementia Treatment Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2024 & 2030
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Dementia Treatment Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Dementia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Regulatory Framework
    • 8.4.2.3. Competitive Insights
    • 8.4.2.4. U.S. Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Regulatory Framework
    • 8.4.3.3. Competitive Insights
    • 8.4.3.4. Canada Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Regulatory Framework
    • 8.4.4.3. Competitive Insights
    • 8.4.4.4. Mexico Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Dementia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Regulatory Framework
    • 8.5.2.3. Competitive Insights
    • 8.5.2.4. UK Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Regulatory Framework
    • 8.5.3.3. Competitive Insights
    • 8.5.3.4. Germany Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Regulatory Framework
    • 8.5.4.3. Competitive Insights
    • 8.5.4.4. France Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Regulatory Framework
    • 8.5.5.3. Competitive Insights
    • 8.5.5.4. Italy Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Regulatory Framework
    • 8.5.6.3. Competitive Insights
    • 8.5.6.4. Spain Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Norway
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Regulatory Framework
    • 8.5.7.3. Competitive Insights
    • 8.5.7.4. Norway Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Denmark
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Regulatory Framework
    • 8.5.8.3. Competitive Insights
    • 8.5.8.4. Denmark Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Sweden
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Regulatory Framework
    • 8.5.9.3. Competitive Insights
    • 8.5.9.4. Sweden Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Dementia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Regulatory Framework
    • 8.6.2.3. Competitive Insights
    • 8.6.2.4. Japan Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Regulatory Framework
    • 8.6.3.3. Competitive Insights
    • 8.6.3.4. China Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Regulatory Framework
    • 8.6.4.3. Competitive Insights
    • 8.6.4.4. India Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Regulatory Framework
    • 8.6.5.3. Competitive Insights
    • 8.6.5.4. South Korea Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Regulatory Framework
    • 8.6.6.3. Competitive Insights
    • 8.6.6.4. Australia Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Regulatory Framework
    • 8.6.7.3. Competitive Insights
    • 8.6.7.4. Thailand Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Dementia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Regulatory Framework
    • 8.7.2.3. Competitive Insights
    • 8.7.2.4. Brazil Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Regulatory Framework
    • 8.7.3.3. Competitive Insights
    • 8.7.3.4. Argentina Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Dementia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Regulatory Framework
    • 8.8.2.3. Competitive Insights
    • 8.8.2.4. South Africa Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Regulatory Framework
    • 8.8.3.3. Competitive Insights
    • 8.8.3.4. Saudi Arabia Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Regulatory Framework
    • 8.8.4.3. Competitive Insights
    • 8.8.4.4. UAE Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Regulatory Framework
    • 8.8.5.3. Competitive Insights
    • 8.8.5.4. Kuwait Dementia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Eisai Co., Ltd.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Eli Lilly and Company
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Novartis AG
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. DAIICHI SANKYO COMPANY, LIMITED
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. AbbVie Inc.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Lundbeck
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Biogen
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Cipla
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Sun Pharmaceutical Industries Ltd.
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Viatris Inc.
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives